Evogene (EVGN) shareholders approve all items at 2025 annual meeting

Rhea-AI Filing Summary

Evogene Ltd. reports that its shareholders approved all proposals presented at its annual general meeting of shareholders held on August 18, 2025, following a one‑week adjournment from the original meeting date. The proposals were described in the proxy statement furnished to the SEC on June 17, 2025. The information in this Form 6‑K is incorporated by reference into Evogene’s existing registration statements on Form F‑3 and several Form S‑8 filings, meaning it now forms part of those registration documents unless later superseded.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-36187

EVOGENE LTD.

  (Translation of Registrant’s Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot

7638517, Israel

  (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Evogene Ltd. (the “Registrant” or the “Company”) hereby announces that the shareholders of the Company approved all the proposals brought before the annual general meeting of shareholders held on August 18, 2025 (following a one-week adjournment from the original meeting date) (the “Meeting”), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (“SEC”), on June 17, 2025, and sent in connection with the Meeting.

The contents of this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565), and Form S-8 (File Nos. 333-193788, 333-201443, 333-203856, 333-259215 and 333-286197) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 18, 2025 EVOGENE LTD.
(Registrant)

By: /s/ Yaron Eldad
——————————————
Yaron Eldad
Chief Financial Officer

FAQ

What did Evogene (EVGN) announce in its August 2025 Form 6-K?

Evogene announced that shareholders approved all proposals brought before its annual general meeting of shareholders held on August 18, 2025, after a one-week adjournment.

When was Evogene Ltd.'s 2025 annual general meeting held?

Evogene's 2025 annual general meeting of shareholders was held on August 18, 2025, following a one-week adjournment from the original meeting date.

Where were the approved proposals for Evogene's 2025 AGM described?

The proposals were described in the proxy statement attached as Exhibit 99.2 to a Form 6-K furnished to the SEC on June 17, 2025 and sent in connection with the meeting.

How does this Form 6-K affect Evogene's registration statements?

The contents of this Form 6-K are incorporated by reference into Evogene's registration statements on Form F-3 (File No. 333-277565) and several Form S-8 filings, becoming part of those documents unless later superseded.

Which Evogene Form S-8 registration statements incorporate this Form 6-K?

This Form 6-K is incorporated by reference into Evogene's Form S-8 registration statements with File Nos. 333-193788, 333-201443, 333-203856, 333-259215 and 333-286197.

What corporate law framework governed Evogene's 2025 shareholder approvals?

The shareholder approvals were made by the requisite majority in accordance with the Israeli Companies Law, 5759-1999, and Evogene's articles of association.